5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.20▲ | 0.20▲ | 0.20▲ | 0.20▲ | 0.20▼ |
MA10 | 0.20▲ | 0.20▲ | 0.20▲ | 0.20▼ | 0.20▲ |
MA20 | 0.20▼ | 0.20▼ | 0.20▼ | 0.20▼ | 0.23▼ |
MA50 | 0.20▲ | 0.20▲ | 0.20▲ | 0.20▲ | 0.27▼ |
MA100 | 0.20▼ | 0.20▼ | 0.20▲ | 0.22▼ | 0.27▼ |
MA200 | 0.20▼ | 0.20▲ | 0.20▲ | 0.27▼ | 0.79▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | 0.000▼ | 0.000▼ | 0.000▼ | 0.000▲ |
RSI | 50.051▲ | 50.312▲ | 50.445▲ | 50.032▲ | 44.651▼ |
STOCH | 65.794 | 51.463 | 47.648 | 59.704 | 48.301 |
WILL %R | -40.909 | -40.909 | -40.909 | -60.000 | -88.954▼ |
CCI | 19.147 | -0.766 | -15.085 | -77.155 | -25.503 |
Wednesday, August 13, 2025 11:33 PM
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease. Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-relat ...
|
Tuesday, August 12, 2025 06:43 AM
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.
|
Tuesday, August 12, 2025 04:12 AM
Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 0.192 | 0.202 | 0.192 | 0.202 | 434,189 |
14/08/25 | 0.204 | 0.2059 | 0.192 | 0.1975 | 489,531 |
13/08/25 | 0.1966 | 0.2074 | 0.1966 | 0.207 | 243,591 |
12/08/25 | 0.206 | 0.206 | 0.1985 | 0.2027 | 377,095 |
11/08/25 | 0.2089 | 0.2089 | 0.20 | 0.20 | 271,257 |
08/08/25 | 0.21 | 0.21 | 0.21 | 0.21 | 158,300 |
07/08/25 | 0.20 | 0.2088 | 0.20 | 0.205 | 411,030 |
06/08/25 | 0.21 | 0.21 | 0.20 | 0.20 | 167,100 |
05/08/25 | 0.20 | 0.20 | 0.20 | 0.20 | 160,300 |
04/08/25 | 0.19 | 0.21 | 0.19 | 0.20 | 228,800 |
|
|
||||
|
|
||||
|
|